Why did Merck delete its PD-1xVEGF and TROP2 trial plan?

The article says Merck briefly posted and then quickly deleted a clinical trial plan pairing its PD-1xVEGF bispecific with its TROP2 ADC. It frames the slip as a meaningful pipeline signal, suggesting observers may read it as a window into Merck’s evolving multi-mechanism oncology combination strategy.